High-density lipoprotein cholesterol and paraoxonase 1 (PON1) genetics and serum PON1 activity in prepubertal children in Spain

Clinical Chemistry and Laboratory Medicine

Volumn 46, Issue 6, 2008, Pages 809-813

  Garcés, Carmen ^a,c   López Simón, Laura ^a   Rubio, Rafael ^a   Benavente, Mercedes ^a   Cano, Beatriz ^a   Ortega, Henar ^b   De Oya, Manuel ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

Children; High density lipoprotein cholesterol; Paraoxonase activity; Paraoxonase polymorphisms

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN;

ARTICLE; ATHEROSCLEROSIS; CHILD; CHOLESTEROL BLOOD LEVEL; ENZYME ACTIVATION; ENZYME POLYMORPHISM; FEMALE; GENE; GENE FREQUENCY; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; NORMAL HUMAN; OXIDATIVE STRESS; PON1 GENE; PREPUBERTY; PRIORITY JOURNAL; SPAIN;

ALLELES; ARYLDIALKYLPHOSPHATASE; CHILD; CHOLESTEROL, HDL; FEMALE; HUMANS; LINEAR MODELS; MALE; POLYMORPHISM, GENETIC; SPAIN;

EID: 44949185370     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2008.163     Document Type: Article

References (36)

1. Steinbrecher UP, Parthasarathy S, Leake DS, Witzum JL, Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA 1984;38:3883-7.
2. Blatter-Garin MC, James RW, Messmer S, Barja F, Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45: identity of K-45 with paraoxonase. Eur J Biochem 1993;21:871-9.
3. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991;286:152-4.
4. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, et al. Protective effect of high-density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally-oxidized low-density lipoprotein. J Clin Invest 1995;96:2882-91.
5. Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993;104:129-35.
6. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998;101:1581-90.
7. Tuzcu EM, Kapadia SR, Tutar E, Ziada KM, Hobbs RE, McCarthy PM, et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults. Evidence from intravascular ultrasound. Circulation 2001;103:2705-10.
8. Berenson GS, Srinivasan SR, Hunter SM, Nicklas TA, Freedman DS, Shear CL, et al. Risk factors in early life as predictors of adult heart disease: The Bogalusa Heart Study. Am J Med Sci 1989;298:141-51.
9. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Drawber TR. High density lipoprotein as a protective factor against coronary heart disease (the Framingham Study). Am J Med 1977;62:707-14.
10. Dwyer T, Iwane H, Dean K, Odagiri Y, Shimomitsu T, Blizzard L, et al. Differences in HDL cholesterol concentrations in Japanese, American and Australian Children. Circulation 1997;96:2830-6.
11. Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heartdisease. Lancet 1975;1:16-9.
12. Garcés C, de Oya M. Cardiovascular risk factors in children. Main findings of the Four Provinces study. Rev Esp Cardiol 2007;60:517-24.
13. Garcés C, Gil A, Benavente M, Viturro E, Cano B, de Oya M. Consistently high plasma HDL-C levels in children in Spain, a country with low cardiovascular mortality. Metabolism 2004;53:1045-7.
14. Garcés C, Benavente M, Ortega H, Rubio R, Lasunción MA, Rodríguez-Artalejo F, et al. Influence of birth weight on the apo E genetic determinants of plasma lipid levels in children. Pediatr Res 2002;52:873-8.
15. Mackness MI, Harty D, Bhatnagar D, Winocour PH, Arrol S, Ishola M, et al. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991;86:193-9.
16. Humbert R, Alder DA, Disteche CM, Hasset C, Omienziski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993;3:73-6.
17. Sentí M, Tomás M, Elosua R, Sala J, Masia R, Marrugat J. The paraoxonase-1 codon 192 polymorphism is associated with fasting total cholesterol and LDL-cholesterol concentrations only in postmenopausal women. The REGICOR study. Clin Chem Lab Med 2002;40:677-83.
18. Scacchi R, Gambina G, Martini MC, Broggio E, Vilardo T, Corbo RM. Different pattern of association of paraoxonase Gln192→Arg polymorphism with sporadic late-onset Alzheimer's disease and coronary artery disease. Neurosci Lett 2003;339:17-20.
19. Ombres D, Pannitteri G, Montali A, Candeloro A, Seccareccia F, Campagna F, et al. The Gln-Arg 192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in Italian patients. Arterioscler Thromb Vasc Biol 1998;18:1611-6.
20. Zama T, Murata M, Matsubara Y, Kawano K, Auki N, Yoshino H, et al. A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol 1997;17:3565-9.
21. Leviev I, James RW. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 2000;20:516-21.
22. Ferre N, Tous M, Paul A, Zamora A, Vendrell JJ, Bardají A, et al. Paraoxonase Gln-Arg (192) and Leu-Met (55) gene polymorphisms and enzyme activity in a population with a low rate of coronary heart disease. Clin Biochem 2002;35:197-203.
23. Sanghera DK, Saha N, Kamboh MI. The codon 55 polymorphism in the paraoxonase1 gene is not associated with the risk of coronary heart disease in Asian Indian and Chinese. Atherosclerosis 1998;136:217-23.
24. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, et al. Paraoxonase status in coronary heart disease. Are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 2001;21:1451-7.
25. Ikeda Y, Suehiro T, Inoue M, Nakauchi Y, Morita T, Arii K, et al. Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin dependent diabetes mellitus. Metabolism 1998;47:598-602.
26. Saha N, Roy AC, Teo S, Ratnam SS. Influence of serum paraoxonase polymorphism on serum lipids and apolipoproteins. Clin Genet 1991;40:277-82.
27. Karikas GA, Kriebardis A, Samara I, Schulpis K, Papachristodoulou M, Fytou-Pallikari A. Serum homocysteine levels and paraoxonase 1 activity in preschool aged children in Greece. Clin Chem Lab Med 2006;44:623-7.
28. Sumegová K, Nagyová Z, Waczulíková I, Žitnanová I, Duracková Z. Activity of paraoxonase 1 and lipid profile in healthy children. Physiol Res 2007;56:351-7.
29. Blatter-Garin MC, Abbott C, Messmer S, Mackness M, Durrington P, Pometta D, James RW. Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem J 1994;304:549-54.
30. Phuntuwate W, Suthisisang C, Koanantakul B, Mackness MI, Mackness B. Paraoxonase 1 status in the Thai population. J Hum Gent 2005;50:293-300.
31. Blatter-Garin MC, Moren X, James RW. Paraoxonase-1 and serum concentrations of HDL-cholesterol and apoA-I. J Lipid Res 2006;47:515-20.
32. Blatter-Garin MC, James RW, Dussoix P, Blanche' H, Passa P, Froguel P, et al. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. J Clin Invest 1997;99:62-6.
33. Mackness B, Durrington PN, Mackness M. Polymorphisms of paraoxonase genes and low-density lipoprotein peroxidation. Lancet 1999;353:468-9.
34. Deakin SP, James RW. Genetic and environmental factors modulating the serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin Sci 2004;107:435-47.
35. Roest M, van Himbergen TM, Barendrecht AD, Peeters PH, van der Schouw YT, Voorbij HA. Genetic and environmental determinants of the PON-1 phenotype. Eur J Clin Invest 2007;37:187-96.
36. Nevin DN, Zambon A, Furlong CE, Richter RJ, Humbert R, Hokanson JE, et al. Paraoxonase genotypes, lipoprotein lipase activity, and HDL. Arterioscler Thromb Vasc Biol 1996;16:1243-9.